# RenovoRx Reports Record Q2 2026 Revenue and Expands RenovoCath Technology Beyond Pancreatic Cancer

> news · REPORTED · 2026-08-12

RenovoRx announced on August 12, 2026 record Q2 2026 revenue and reported commercial momentum including multiple cancer center activations, alongside expansion of the RenovoCath drug-delivery device application beyond locally advanced pancreatic cancer. The company highlighted all three milestones set for the business were achieved in the quarter.

About RenovoRx: RenovoRx is a life sciences company that commercializes RenovoCath, a patented FDA-cleared intra-arterial drug-delivery catheter device for targeted oncology therapy delivery, initially focused on locally advanced pancreatic cancer.

- Company: RenovoRx
- Sector: oncology
- Primary source: https://www.sec.gov/Archives/edgar/data/0001574094/000119312526349157/rnxt-ex99_1.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.